---
title: "2025/26 Subclade-Specific Influenza Vaccine Effectiveness for A(H3N2), A(H1N1)pdm09, and B/Victoria"
id: "medrxiv-11-2025-26-subclade-specific-influenza-a-and-b-vaccine-effectiveness-estimates-and"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-11-2025-26-subclade-specific-influenza-a-and-b-vaccine-effectiveness-estimates-and"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.10.26362769v1?rss=1"
published_at: "2026-09-12T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# 2025/26 Subclade-Specific Influenza Vaccine Effectiveness for A(H3N2), A(H1N1)pdm09, and B/Victoria
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-11-2025-26-subclade-specific-influenza-a-and-b-vaccine-effectiveness-estimates-and
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.10.26362769v1?rss=1)
- **Published At:** 2026-09-12T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study used a test-negative design among outpatients with medically attended acute respiratory illness in Canada between November and April to estimate **vaccine effectiveness** (VE) for the 2025/26 influenza season. - Of 9,047 specimens, 2,809 (31%) were influenza-positive; 82% (2,306/2,809) were influenza A and 18% (504/2,809) influenza B. - Among subtyped influenza A, 85% (1,848/2,169) were **A(H3N2)**. Sixty percent (1,099/1,848 = 59%) of A(H3N2) viruses were sequenced; 87% (956/1,099) were subclade K, which was antigenically mismatched to the subclade J.2 vaccine strain. - VE against **A(H3N2)** overall was 38% (95% CI 27%–47%) and 33% (19%–45%) specifically for subclade K. - For **A(H1N1)pdm09**, 69% (222/323) of viruses were sequenced; nearly all (n=218) belonged to clade 5a.2a.1, including D.3.1 (21%, n=47) and D.3.1.1 (77%, n=171), which were antigenically matched to the subclade D vaccine. - VE estimates for **A(H1N1)pdm09** were 28% (4%–47%) overall, −21% (−144%–40%) for subclade D.3.1, and 44% (14%–64%) for D.3.1.1. - Of influenza B viruses, 82% (413/504) were sequenced and all were **B/Victoria** lineage; subclade C.3 (18%, n=74) was antigenically mismatched and had D197N gain-of-glycosylation, while subclade C.5 (82%, n=339) was antigenically matched to the vaccine. - VE against influenza B overall was 55% (41%–66%); for subclades C.3 and C.5 VE was 10% (−60%–49%) and 68% (51%–79%), respectively. - Authors conclude the 2025/26 vaccine reduced risk of A(H3N2), A(H1N1)pdm09 and B/Victoria by over one-third, one-quarter and one-half, respectively, and note that laboratory indicators of antigenic match do not always predict epidemiological VE. - Ethical approvals or waivers were obtained or documented across participating provinces; sequencing data are available on GISAID under EPI_SET_260819zv. Funding sources and competing interests are declared in the source.
## Clinical Analysis & Structured Key Points
2025/26 subclade-specific influenza A and B vaccine effectiveness estimates and discordant laboratory-based indicators of vaccine match or mismatch | medRxiv Skip to main content 2025/26 subclade-specific influenza A and B vaccine effectiveness estimates and discordant laboratory-based indicators of vaccine match or mismatch Lea Separovic , Samantha E Kaweski , Michelle B Cox , Yuping Zhan , Suzana Sabaiduc , Romy Olsha , Maan Hasso , Richard G Mather , Sara Carazo , Christine Lacroix , Isabelle Meunier , Lila N Salhi , James A Dickinson , Nathan Zelyas , Agatha N Jassem , Katie Dover , Charlene Ranadheera , Ruimin Gao , Nathalie Bastien , Danuta M Skowronski doi: https://doi.org/10.64898/2026.09.10.26362769 Lea Separovic 1 British Columbia Centre for Disease Control; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Samantha E Kaweski 1 British Columbia Centre for Disease Control; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michelle B Cox 1 British Columbia Centre for Disease Control; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yuping Zhan 1 British Columbia Centre for Disease Control; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Suzana Sabaiduc 1 British Columbia Centre for Disease Control; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Romy Olsha 2 Public Health Ontario; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maan Hasso 2 Public Health Ontario; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Richard G Mather 2 Public Health Ontario; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sara Carazo 3 Institut National de Sante Publique du Quebec; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christine Lacroix 3 Institut National de Sante Publique du Quebec; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Isabelle Meunier 3 Institut National de Sante Publique du Quebec; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lila N Salhi 3 Institut National de Sante Publique du Quebec; Find this author on Google Scholar Find this author on PubMed Search for this author on this site James A Dickinson 4 University of Calgary; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nathan Zelyas 5 Public Health Laboratory, Alberta Precision Laboratories; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Agatha N Jassem 1 British Columbia Centre for Disease Control; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Katie Dover 1 British Columbia Centre for Disease Control; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Charlene Ranadheera 6 National Microbiology Laboratory Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ruimin Gao 6 National Microbiology Laboratory Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nathalie Bastien 6 National Microbiology Laboratory Find this author on Google Scholar Find this author on PubMed Search for this author on this site Danuta M Skowronski 1 British Columbia Centre for Disease Control; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: danuta.skowronski{at}bccdc.ca Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: The 2025/26 influenza season included A(H3N2) subclade K predominance with A(H1N1)pdm09 co-circulation and subsequent prolonged influenza B activity. The Canadian Sentinel Practitioner Surveillance Network reports vaccine effectiveness (VE) in the context of genetic and antigenic relatedness to circulating viruses. Methods: We estimated VE by test-negative design among outpatients with medically-attended acute respiratory illness between November and April. We characterized case viruses by whole genome sequencing and hemagglutination inhibition assay. Results: Among 2809/9047 (31%) influenza-positive specimens, 82% (2306/2809) were influenza A with 18% (504/2809) influenza B. Of subtyped influenza A, 85% (1848/2169) were A(H3N2). We sequenced 59% (1099/1848) of A(H3N2) viruses, with 87% (956/1099) subclade K, antigenically-mismatched to subclade J.2 vaccine. VE against A(H3N2) and subclade K was 38% (95% confidence interval: 27%-47%) and 33% (19%-45%). We sequenced 69% (222/323) of A(H1N1)pdm09 viruses, virtually all (n=218) clade 5a.2a.1, including subclades D.3.1 (21%; n=47) and D.3.1.1 (77%; n=171), antigenically-matched to subclade D vaccine. VE against A(H1N1)pdm09, subclades D.3.1 and D.3.1.1 was 28% (4%-47%), -21% (-144%-40%) and 44% (14%-64%). We sequenced 82% (413/504) of influenza B viruses, all B/Victoria, including antigenically-mismatched subclade C.3 (18%; n=74) with D197N gain-of-glycosylation, and antigenically-matched subclade C.5 (82%; n=339) relative to subclade C vaccine. VE against influenza B, subclades C.3 and C.5 was 55% (41%-66%), 10% (-60%-49%) and 68% (51%-79%). Conclusions: The 2025/26 influenza vaccine reduced the risk of A(H3N2), A(H1N1)pdm09 and B/Victoria by over one-third, one-quarter and one-half, respectively. Laboratory-based indicators of vaccine match remain uncertain proxies for actual vaccine protection, reinforcing importance of annual epidemiological monitoring of VE. Competing Interest Statement DMS is Principal Investigator on grants received to her institution from the Public Health Agency of Canada, Canadian Institutes of Health Research, and the Pacific Public Health Foundation. JAD reports funding from Alberta Health paid to his institution. ANJ reports funding from the Canadian Institutes of Health Research, Genome Canada, and Genome British Columbia paid to her institution, and financial support from the Canadian Institutes of Health Research and Canadian Association for Clinical Microbiology and Infectious Diseases for travel expenses, with none of the above pertaining to the current study. ANJ also reports committee membership in the Canadian Association for Clinical Microbiology and Infectious Diseases (no payments made) and the British Columbia Diagnostic Accreditation Program (payments made to ANJ). SC reports funding from the Public Health Agency of Canada paid to her institution, but not pertaining to the current study. Other authors have no conflicts of interest to declare. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical approval was obtained or waived in the four participating provinces as follows. In Alberta, the Conjoint Health Research Ethics Board of the University of Calgary gave ethical approval for this work (REB150587). In British Columbia, both the Clinical and Behavioural Research Ethics Boards of the University of British Columbia waived ethical approval for this work because such evaluations are considered within the core public health mandate of the BC Centre for Disease Control (BCCDC). In Ontario, the Ethics Review Board of Public Health Ontario determined this work did not require ongoing review and waived ethical approval for this work, as the activities are considered routine public health practice in fulfilment of Public Health Ontario's legislated mandate, and not research. In Quebec, the Research Ethics Board of the Centre hospitalier universitaire de Quebec waived ethical approval for this work as such evaluations are similarly considered part of core public health surveillance. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Sequencing data for included viruses that met provincial/national criteria for upload and their submitting/contributing laboratories can be found on GISAID using the Epi Set ID: EPI_SET_260819zv (https://doi.org/10.55876/gis8.260819zv). https://doi.org/10.55876/gis8.260819zv Funder Information Declared British Columbia Ministry of Health Pacific Public Health Foundation Alberta Health and Wellness Public Health Ontario Ministère de la santé et des services sociaux du Québec Canadian Institutes of Health Research , FP5-203220 Public Health Agency of Canada , 2324-HQ-000038 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 12, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following 2025/26 subclade-specific influenza A and B vaccine effectiveness estimates and discordant laboratory-based indicators of vaccine match or mismatch Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share 2025/26 subclade-specific influenza A and B vaccine effectiveness estimates and discordant laboratory-based indicators of vaccine match or mismatch Lea Separovic , Samantha E Kaweski , Michelle B Cox , Yuping Zhan , Suzana Sabaiduc , Romy Olsha , Maan Hasso , Richard G Mather , Sara Carazo , Christine Lacroix , Isabelle Meunier , Lila N Salhi , James A Dickinson , Nathan Zelyas , Agatha N Jassem , Katie Dover , Charlene Ranadheera , Ruimin Gao , Nathalie Bastien , Danuta M Skowronski medRxiv 2026.09.10.26362769; doi: https://doi.org/10.64898/2026.09.10.26362769 Share This Article: Copy Citation Tools 2025/26 subclade-specific influenza A and B vaccine effectiveness estimates and discordant laboratory-based indicators of vaccine match or mismatch Lea Separovic , Samantha E Kaweski , Michelle B Cox , Yuping Zhan , Suzana Sabaiduc , Romy Olsha , Maan Hasso , Richard G Mather , Sara Carazo , Christine Lacroix , Isabelle Meunier , Lila N Salhi , James A Dickinson , Nathan Zelyas , Agatha N Jassem , Katie Dover , Charlene Ranadheera , Ruimin Gao , Nathalie Bastien , Danuta M Skowronski medRxiv 2026.09.10.26362769; doi: https://doi.org/10.64898/2026.09.10.26362769 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Public and Global Health Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (898) Anesthesia (330) Cardiovascular Medicine (4804) Dentistry and Oral Medicine (478) Dermatology (414) Emergency Medicine (648) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1625) Epidemiology (15924) Forensic Medicine (32) Gastroenterology (1202) Genetic and Genomic Medicine (7037) Geriatric Medicine (732) Health Economics (1064) Health Informatics (5032) Health Policy (1432) Health Systems and Quality Improvement (1757) Hematology (584) HIV/AIDS (1343) Infectious Diseases (except HIV/AIDS) (16282) Intensive Care and Critical Care Medicine (1170) Medical Education (667) Medical Ethics (153) Nephrology (722) Neurology (7259) Nursing (366) Nutrition (1080) Obstetrics and Gynecology (1240) Occupational and Environmental Health (1004) Oncology (3600) Ophthalmology (1049) Orthopedics (397) Otolaryngology (451) Pain Medicine (470) Palliative Medicine (139) Pathology (706) Pediatrics (1795) Pharmacology and Therapeutics (737) Primary Care Research (764) Psychiatry and Clinical Psychology (5884) Public and Global Health (9742) Radiology and Imaging (2412) Rehabilitation Medicine and Physical Therapy (1448) Respiratory Medicine (1247) Rheumatology (640) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (775) Toxicology (107) Transplantation (304) Urology (290)
## Related Clinical Research

- [Influenza vaccine reduces mortality and ICU use among Brazilian SARI inpatients, 2023–2025](https://medichelpline.com/clinical-feed/medrxiv-14-protective-effect-of-influenza-vaccine-in-brazilian-patients-hospitalised-for.md)
- [Pennsylvania reports third measles-related death amid ongoing outbreak; other health headlines](https://medichelpline.com/clinical-feed/stat-news-2-pennsylvania-records-third-measles-related-death-amid-outbreak.md)
- [Increased risk of acute gastroenteritis after COVID-19 hospitalisation: a retrospective England an](https://medichelpline.com/clinical-feed/medrxiv-3-risk-of-acute-gastroenteritis-following-covid-19-exposure-a-retrospective.md)
- [Medical groups, Vaccine Integrity Project issue joint RSV, Covid-19, and influenza vaccine guidanc](https://medichelpline.com/clinical-feed/stat-news-0-doctors-groups-release-vaccination-guidelines-ahead-of-respiratory-illness.md)
- [FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for adults 50+: what clinicians should know](https://medichelpline.com/clinical-feed/medical-news-today-0-moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.